ArticleNature communications2024
Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 75 citations in OpenAlex.
- A stealth delivery platform for B cell-based immunity.Molecular therapy. Nucleic acids · 2026Article
- Intranasal DNA nanocarrier vaccines with surface-patterned antigens enhance efficacy against respiratory syncytial virus.Nature materials · 2026Article
- Bioengineering DNA-based hydrogels for regenerative medicine: A review of programmable design, chemical synthesis and therapeutic potential.Materials today. Bio · 2026Review
- De novo design of DNA origami with a generative diffusion model.Nature communications · 2026Article
- DNA origami-based virus-like particles: a new class of HIV vaccine candidates with superior immunogenic properties.Signal transduction and targeted therapy · 2026Article
- Programmable Lipid Functionalization of Nucleic Acid Nanoparticles Modulates Liver Cell-Type Targeting.ACS applied materials & interfaces · 2026Article
- Development and Immunogenicity Evaluation of an RSV Recombinant Vaccine Displaying a Conserved Domain of RSV G.Vaccines · 2026Article
- DNA origami vaccines program antigen-focused germinal centers.Science (New York, N.Y.) · 2026Article
- Resolving DNA origami structural integrity and pharmacokinetics in vivo.Nature nanotechnology · 2026Article
- Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen.Nature communications · 2026Article
- Intelligence Disclosure on Deploying SpyTag/SpyCatcher for Nanoparticle Assembly.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Characterization of Non-Specific Electrostatic Interactions of Cationic Peptides with DNA Origami and Their Functional Consequences.Small methods · 2026Article
- Unraveling the Folding Dynamics of DNA Origami Structures.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning.Nature biotechnology · 2025Article
- Nucleic Acid Nanoparticles Redefine Traditional Regulatory Terminology: The Blurred Line between Active Pharmaceutical Ingredients and Excipients.ACS nano medicine · 2025Article
- From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Display of clustered antigen by follicular dendritic cells tunes B-cell receptor activation.bioRxiv : the preprint server for biology · 2025Article
- Engineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Effects of Oligolysine-Polyethylene Glycol Coating on the Biodistribution of Wireframe DNA Origami Nanosheets in Zebrafish Embryos.ACS nano · 2025Article
- Germinal center immune dynamics: challenges for effective vaccination in the elderly.Immunotherapy · 2025Review
Corrections and comments
- Update of
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
Protein-based virus-like particles (P-VLPs) are commonly used to spatially organize antigens and enhance humoral immunity through multivalent antigen display. However, P-VLPs are thymus-dependent antigens that are themselves immunogenic and can induce B cell responses that may neutralize the platform. Here, we investigate thymus-independent DNA origami as an alternative material for multivalent antigen display using the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, the primary target of neutralizing antibody responses. Sequential immunization of mice with DNA-based VLPs (DNA-VLPs) elicits protective neutralizing antibodies to SARS-CoV-2 in a manner that depends on the valency of the antigen displayed and on T cell help. Importantly, the immune sera do not contain boosted, class-switched antibodies against the DNA scaffold, in contrast to P-VLPs that elicit strong B cell memory against both the target antigen and the scaffold. Thus, DNA-VLPs enhance target antigen immunogenicity without generating scaffold-directed immunity and thereby offer an important alternative material for particulate vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.